Kiniksa reports 62% growth in ARCALYST revenue to $677.5 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Kiniksa Pharmaceuticals Provides Corporate Update
January 12, 2026 7:30 AM EST ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth
ARCALYST 2026 net product revenue expected to be $900 - $920 million
KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026
KPL-1161 Phase 1 trial planned to initiate by year end
Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited)
LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq:... More
